Skip to main content
. 2017 Jul 12;8(49):85276–85289. doi: 10.18632/oncotarget.19205

Figure 6. Gain of function of miR-200b-3p or miR-429-5p arrests cell-cycle progression in TNBC cells.

Figure 6

(A) Flow cytometry results demonstrating that miR-200b-3p arrested more MDA-MB-231 TNBC cells than negative control (NC) cells at G2/M phase (Student t test; p < 0.05). (B) Flow cytometry results demonstrating that miR-429-5p arrested more MDA-MB-231 cells than NC cells at G0/G1 phase (Student t test; p < 0.05). (C–E) Representative Western blots showing that miR-200b-3p and miR-429-5p suppressed CDK4/CDK6/cyclin D1 and CDK2/cyclin E1 protein expression in MDA-MB-231 and HCC1937 TNBC cells. Three independent experiments were performed. % of cells or gray scale images of each assay were quantitated or scanned and presented as a bar chart in which the vertical axis is the mean ± SD. * indicates statistical differences at p < 0.05, ** indicates statistical differences at p < 0.01, and *** indicates statistical differences at p < 0.001.